Profile data is unavailable for this security.
About the company
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
- Revenue in USD (TTM)16.45m
- Net income in USD-14.11m
- Incorporated2005
- Employees14.00
- LocationOcuphire Pharma Inc37000 Grand River Ave., Suite 120FARMINGTON HILLS 48335United StatesUSA
- Phone+1 (248) 681-9815
- Fax+1 (240) 268-5310
- Websitehttps://www.ocuphire.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | 2.40m | -107.83m | 23.49m | 74.00 | -- | -- | -- | 9.78 | -3.56 | -3.56 | 0.074 | -1.84 | 0.0234 | 0.5941 | 3.87 | 32,472.97 | -104.93 | -74.57 | -150.29 | -84.06 | 43.07 | -- | -4,487.39 | -32,300.74 | 2.25 | -10.10 | 3.59 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Polypid Ltd | 0.00 | -24.70m | 24.33m | 59.00 | -- | 10.37 | -- | -- | -9.65 | -9.65 | 0.00 | 0.3337 | 0.00 | -- | -- | 0.00 | -107.89 | -76.92 | -164.39 | -89.61 | -- | -- | -- | -- | -- | -24.21 | 0.8425 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Bio Essence Corp | 593.21k | -1.02m | 25.09m | 12.00 | -- | -- | -- | 42.29 | -0.0278 | -0.0156 | 0.0158 | -0.0458 | 0.3305 | -- | 21.20 | -- | -57.09 | -46.10 | -- | -- | 25.05 | 33.89 | -172.74 | -111.21 | -- | -59.99 | 7.03 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
| KALA BIO Inc | 0.00 | -38.72m | 26.68m | 43.00 | -- | 1.94 | -- | -- | -13.95 | -13.95 | 0.00 | 2.98 | 0.00 | -- | -- | 0.00 | -60.45 | -57.83 | -78.16 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.36 | 0.7174 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Acasti Pharma Inc | 0.00 | -11.45m | 27.17m | 32.00 | -- | 0.4578 | -- | -- | -1.22 | -1.22 | 0.00 | 5.85 | 0.00 | -- | -- | -- | -16.04 | -31.68 | -16.57 | -33.95 | -- | -- | -- | -56,271.43 | -- | -37.80 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Dare Bioscience Inc | 2.84m | -7.20m | 27.86m | 23.00 | -- | 10.43 | -- | 9.81 | -1.07 | -1.07 | 0.3579 | 0.3126 | 0.1213 | -- | 3.85 | 123,462.20 | -30.76 | -109.51 | -191.39 | -246.26 | 0.8477 | -- | -253.60 | -1,104.55 | -- | -- | 0.00 | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Equillium Inc | 42.62m | -8.32m | 30.11m | 45.00 | -- | 1.34 | -- | 0.7064 | -0.2377 | -0.2377 | 1.20 | 0.6333 | 0.8388 | -- | 8.85 | 968,704.60 | -16.37 | -46.81 | -29.58 | -57.36 | -- | -- | -19.52 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Incannex Healthcare Inc | -100.00bn | -100.00bn | 30.95m | -- | -- | 2.19 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Fortress Biotech Inc | 82.62m | -49.54m | 34.11m | 186.00 | -- | 1.89 | -- | 0.4128 | -3.71 | -3.71 | 6.05 | 0.7915 | 0.5063 | 2.36 | 6.07 | 444,215.10 | -65.90 | -52.50 | -113.69 | -99.46 | 68.77 | 63.17 | -130.17 | -236.94 | 1.24 | -13.40 | 1.26 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Ocuphire Pharma Inc | 16.45m | -14.11m | 36.42m | 14.00 | -- | 0.8886 | -- | 2.21 | -0.5507 | -0.5507 | 0.6871 | 1.56 | 0.3726 | -- | 6.53 | 1,174,929.00 | -31.95 | -58.31 | -36.01 | -65.94 | -- | -- | -85.75 | -137.92 | -- | -10.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Eyenovia Inc | 31.41k | -37.28m | 38.53m | 57.00 | -- | -- | -- | 1,226.56 | -0.7897 | -0.7897 | 0.0007 | -0.0425 | 0.0013 | -- | 0.0418 | 551.05 | -154.24 | -80.31 | -262.28 | -117.70 | -1,489.11 | -- | -118,693.60 | -680.95 | 0.267 | -40.92 | 1.20 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 41.86m | 317.00 | -- | 0.4977 | 31.19 | 0.3482 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Aadi Bioscience Inc | 23.82m | -65.44m | 47.51m | 70.00 | -- | 0.6029 | -- | 1.99 | -2.43 | -2.43 | 0.8829 | 3.20 | 0.1884 | 0.6393 | 4.96 | 267,606.80 | -51.76 | -50.25 | -60.12 | -56.15 | 87.18 | -- | -274.77 | -473.97 | 3.92 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Immix Biopharma Inc | 0.00 | -19.02m | 49.41m | 14.00 | -- | 2.07 | -- | -- | -0.8411 | -0.8411 | 0.00 | 0.871 | 0.00 | -- | -- | 0.00 | -86.64 | -- | -100.82 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
Data as of Sep 23 2024. Currency figures normalised to Ocuphire Pharma Inc's reporting currency: US Dollar USD
9.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 986.41k | 3.81% |
| Geode Capital Management LLCas of 30 Jun 2024 | 265.85k | 1.03% |
| Richmond Brothers, Inc.as of 31 Mar 2024 | 227.46k | 0.88% |
| MAI Capital Management LLCas of 31 Mar 2024 | 223.97k | 0.86% |
| Rice, Hall, James & Associates LLCas of 30 Jun 2024 | 223.59k | 0.86% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 209.94k | 0.81% |
| Knoll Capital Management LPas of 31 Mar 2024 | 100.00k | 0.39% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 91.96k | 0.36% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 70.47k | 0.27% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 51.93k | 0.20% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
